Follistatin-344: What the Evidence Actually Shows

Follistatin-344 (FS344) is sold in the bodybuilding and peptide-research market as an injectable myostatin inhibitor — a way to block the natural brake on muscle growth. Checked directly against the published literature rather than the marketing framing, the real evidence for this compound splits sharply along a line the market doesn't advertise: the only genuinely positive human results come from gene therapy, a completely different delivery method than what's actually injected and sold, and the injected recombinant protein itself has a real, published case series of eye injury tied to it directly.

What it actually is

Follistatin is a naturally occurring protein that binds and neutralizes myostatin and activin, two signaling molecules in the TGF-beta superfamily that restrain skeletal muscle growth — blocking them is the entire mechanistic premise behind every follistatin product sold for muscle building. Follistatin exists in the body as multiple alternatively-spliced isoforms, and the choice of which one matters directly to this article: FST-344, unlike the more common FST-315 isoform, has reduced binding affinity for cell-surface heparan sulfate proteoglycans — a distinction sourced directly to the reasoning researchers gave for choosing it in a real human trial, discussed below, not to a marketing description¹.

The only real positive human evidence: gene therapy, not an injected protein

This is the single most important distinction in this article, and it's worth stating before anything else: every genuinely positive human result for FST-344 located in this review comes from gene therapy — a viral or plasmid vector that makes a patient's own muscle cells produce the protein internally — not from injecting the recombinant protein itself. A real Phase 1/2a clinical trial delivered an AAV1 viral vector carrying the FS344 gene (written AAV1.CMV.FS344) by direct bilateral intramuscular injection into the quadriceps of six Becker muscular dystrophy patients, a genetic muscle-wasting disease with no treatment at the time¹. The trial's own stated reason for choosing this specific isoform over the more common FST-315: "we used the alternatively spliced FS344 to avoid potential binding to off target sites¹." Results were real and, for most patients, positive: two of three patients in the lower-dose cohort improved 58 and 125 meters on the 6-minute walk test; two of three in the higher-dose cohort improved 108 and 29 meters; one patient in each cohort showed no change. No adverse effects were reported, and muscle biopsies showed reduced fibrosis and muscle hypertrophy consistent with the functional improvement¹. A follow-up trial used the same AAV1.CMV.FS344 gene-therapy approach in six patients with sporadic inclusion body myositis, a different muscle-wasting disease, finding a real annualized improvement of +56.0 meters/year in treated patients versus a decline of -25.8 meters/year in untreated matched controls (p=0.01)².

A third, more recent trial pushes this same gene-therapy approach further into the space the black market actually occupies: a completed Phase 1 study, sponsored by a company called Minicircle, tested an injectable PLASMID DNA — not a virus — carrying the FST344 gene in 43 participants, run at an offshore clinical-research site in Roatan, Honduras, explicitly outside FDA jurisdiction³. This is a real, registered, completed trial, and it is precisely the same delivery logic as the AAV trials above — a gene vector that makes the body produce its own follistatin, rather than an injected dose of the protein itself. As of this article, no peer-reviewed publication of that trial's results has been located.

What's actually injected and sold: a genuinely different product, with a real published harm signal

Here is where the market's actual product diverges sharply from the evidence above. What's sold on the black market as "follistatin 344" is not a gene-therapy vector — it's the recombinant protein itself, injected directly. Two independent doping-control chemistry papers purchased and laboratory-tested 17 real black-market products labeled "follistatin 344," and the results are worth reporting precisely: only 9 of the 17 tested products actually contained follistatin at all. Several of the others contained entirely different growth-promoting peptides instead — the study names "MGF" (mechano growth factor) and "GHRP-2" explicitly as substitutes found in mislabeled products⁴ — the same GHRP-2 covered in this site's own GHRP-2 evidence review. All 9 of the genuine products, notably, contained "His-tagged FS344" — a purification-tag artifact of recombinant bacterial (E. coli) production that would not appear in any pharmaceutical-grade candidate, and a real, checkable identity marker this study used to build its own detection method⁴. Follistatin is confirmed prohibited under the World Anti-Doping Agency's 2019 Prohibited List, chapter S4⁴.

Set against that black-market backdrop, a real, published, peer-reviewed 11-patient case series reports a direct human harm signal tied to exactly this product: 11 male bodybuilders (mean age 36.8) were diagnosed with central serous chorioretinopathy — a retinal condition causing decreased visual acuity — after injecting follistatin-344 to increase muscle mass. Every one of the 11 patients had "a history of injecting complete 1 mg vials of follistatin-344 subcutaneously in the abdomen⁵." Ten had unilateral disease, one bilateral. In the eight patients with a single prior injection, the fluid under the retina resolved on its own after an average of 2.3 months. Three patients with a history of multiple injections developed recurrent CSCR⁵. The study's own conclusion states plainly: "Follistatin-344 injection can be considered as a risk factor for CSCR⁵." This is a real, specific, peer-reviewed human harm finding, directly tied to the exact product form (1 mg vials, subcutaneous, abdomen) this compound is actually sold and used as — not a theoretical safety concern extrapolated from animal data.

The regulatory picture

No FDA-approved product exists in any form. A live, full-text search of FDA's current 503A Bulks List (May 14, 2026) and FDA's companion significant-safety-risks page found zero mention of "follistatin" in either document — unlike GHRP-2 and GHRP-6 elsewhere in this batch, follistatin has never been formally nominated for FDA's compounding-substance review process at all, at least as far as either current document shows. DailyMed's structured-product-label search and openFDA's Drugs@FDA database both return zero results. openFDA's FAERS database returns zero reports for "follistatin" — the smallest, or tied-smallest, adverse-event count of any compound in this five-article batch, notable given the real published CSCR case series above; a zero FAERS count reflects voluntary reporting volume for an unapproved, black-market product, not an absence of real-world harm.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell follistatin-344 — this site's own identity-layer research confirms it is not tagged to any reviewed seller. The real evidence for this compound splits cleanly along a line worth holding onto: gene-therapy delivery (AAV or plasmid vectors making a patient's own cells produce the protein) has real, published, mostly-positive human results, with no reported adverse effects, in two specific rare muscle-wasting diseases. The injected recombinant protein — what's actually sold and used in the bodybuilding market this compound is marketed to — has a real, peer-reviewed, published case series tying it directly to a retinal injury, and independent lab testing found nearly half of tested black-market products either didn't contain follistatin at all or were adulterated with other unlisted peptides. Our reconstitution calculator does the vial-to-syringe arithmetic on the numbers you enter — the published case series above confirms the real retail vial size (1 mg) this calculator is built around, but it cannot confirm what's actually in any given vial, which is precisely the identity problem the doping-control literature documented directly. If you're researching other muscle-growth-marketed peptides this site covers, our GHRP-2, GHRP-6, and Hexarelin evidence reviews cover a mechanistically different class (GH secretagogues rather than myostatin inhibitors) marketed for a similar muscle-building purpose.